Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/

Latest From Taisho Pharmaceutical Co., Ltd.

India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results

Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.

Sales & Earnings Generic Drugs

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model label to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.

Drug Approval Standards FDA

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model DFl to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.

Drug Approval Standards FDA

Hikma Expectations Stabilize – But Generics Still Set To Take A Hit

After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
  • Other Names / Subsidiaries
    • Hoepharma Holdings Sdn. Bhd.
    • Taisho Toyama Pharmaceutical Co., Ltd.
    • TOKUHON Corporation
    • UPSA SAS
UsernamePublicRestriction

Register